Neuroendocrine Tumors Therapeutics Market By Drug Class (Somatostatin Analogues,(Octreotide, Lanreotide, Pasireotide), Chemotherapeutics (Fluorouracil (5-FU), Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil), Streptozocin, Temozolomide (Temodar), Capecitabine (Xeloda), Dacarbazine (DTIC), Oxaliplatin (Eloxatin)), Targeted Therapeutics, (Sunitinib, Everolimus,Others)), By Indication (Lung NET, Others NET, Gastrointestinal NET, Pancreatic NET), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

Neuroendocrine Tumors Therapeutics Market size was valued at USD 1.6 billion in 2023 and is poised to grow at a significant CAGR of 8.2% from 2024-2030. Neuroendocrine tumors (NET) are abnormal growths that begin in neuroendocrine cells. Neuroendocrine which are similar to the nerve cells and hormones producing cells. Neuroendocrine tumors are rare and can occur anywhere in the body. Most neuroendocrine tumors occur in the small intestine, lungs, rectum, appendix, and pancreas. Neuroendocrine tumors can be noncancerous (benign) or cancerous (malignant). NETs will arise from several neuroendocrine cells whose normal functions are to serve at the neuroendocrine interface.

Neuroendocrine cells will present throughout the body where hormones are produced but not only in the endocrine glands. The neuroendocrine tumor therapeutics market is expected to grow owing to an increase in initiatives taken by various international organizations like the American Association for Cancer Research and the World Health Organization to treat neuroendocrine tumors are expected to drive the growth of the market. AACR provided a $250,000 fund for the Prevention of neuroendocrine tumors. The rise in health care expenditure and an increase in the prevalence rate of neuroendocrine tumors in developing regions is anticipated to drive the neuroendocrine tumor therapeutics market growth.  Though the market is expected to witness healthy growth, the lack of skilled healthcare professionals and lower adoption of advanced treatment technologies in developing economies are key restraints for the neuroendocrine tumors market.

Global Neuroendocrine Tumors Therapeutics Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

8.2%

Largest Market

North-America

Fastest Growing Market

Asia Pacific
Neuroendocrine Tumors Therapeutics Market Dynamics

The neuroendocrine tumors treatment market is expected to gain steady traction in the foreseeable future as there are many novel drugs are in pipeline. Increase in NET incidence and prevalence globally. As per the estimation of Canadian Cancer Society (CCS), about 315 individuals were diagnosed with endocrine cancers in 2012 in Canada and rate is raising with early stage diagnosis and migration. Moreover, rise in survival rate of neuroendocrine tumors by treating with various medications are expected to have a positive impact on neuroendocrine tumors market. According to the study published in the JAMA Oncology Journal (2017), the survival rate for all neuroendocrine tumour treatment have improved, especially for distant-stage gastrointestinal neuroendocrine tumour treatment and pancreatic neuroendocrine tumour treatment.

Global Neuroendocrine Tumors Therapeutics Market Segmentation

By Drug Class
  • Somatostatin Analogues
    • Octreotide
    • Lanreotide
    • Pasireotide
  • Chemotherapeutics
    • Fluorouracil (5-FU)
    • Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)
    • Streptozocin
    • Temozolomide (Temodar)
    • Capecitabine (Xeloda)
    • Dacarbazine (DTIC)
    • Oxaliplatin (Eloxatin)
  • Targeted Therapeutics
    • Sunitinib
    • Everolimus
  • Others
By Indication
  • Lung NET
  • Others NET
  • Gastrointestinal NET
  • Pancreatic NET
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Frequently Asked Questions

The neuroendocrine tumors therapeutics market size was valued at USD 1.6 billion in 2023

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

The neuroendocrine tumors therapeutics market key players are Pfizer Inc., (U.S) Eli Lilly & Company (U.S.) Novartis AG (Switzerland) F. Hoffmann-La Roche Ltd.(Switzerland) Ipsen (France) Amgen, Inc. (U.S.) Teva Pharmaceuticals, Ltd. (Israel) Bristol-Myers Squibb (U.S.)

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
1.Executive Summary
2.Global Neuroendocrine Tumors Therapeutics Market Introduction 
2.1.Global Neuroendocrine Tumors Therapeutics Market  - Taxonomy
2.2.Global Neuroendocrine Tumors Therapeutics Market  - Definitions
2.2.1.Drug Class
2.2.2.Indication
2.2.3.Distribution Channel
2.2.4.Region
3.Global Neuroendocrine Tumors Therapeutics Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Neuroendocrine Tumors Therapeutics Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Neuroendocrine Tumors Therapeutics Market  By Drug Class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Somatostatin Analogues 
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Chemotherapeutics 
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Targeted Therapeutics 
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Others
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
6.Global Neuroendocrine Tumors Therapeutics Market  By Indication, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Lung NET
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Others NET
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Gastrointestinal NET
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Pancreatic NET
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
7.Global Neuroendocrine Tumors Therapeutics Market  By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Others
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8.Global Neuroendocrine Tumors Therapeutics Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Neuroendocrine Tumors Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Somatostatin Analogues 
9.1.2.Chemotherapeutics 
9.1.3.Targeted Therapeutics 
9.1.4.Others
9.2.  Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Lung NET
9.2.2.Others NET
9.2.3.Gastrointestinal NET
9.2.4.Pancreatic NET
9.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospital Pharmacies
9.3.2.Retail Pharmacies
9.3.3.Others
9.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Neuroendocrine Tumors Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Somatostatin Analogues 
10.1.2.Chemotherapeutics 
10.1.3.Targeted Therapeutics 
10.1.4.Others
10.2.  Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Lung NET
10.2.2.Others NET
10.2.3.Gastrointestinal NET
10.2.4.Pancreatic NET
10.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital Pharmacies
10.3.2.Retail Pharmacies
10.3.3.Others
10.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
10.4.7.
11.Asia Pacific (APAC) Neuroendocrine Tumors Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Somatostatin Analogues 
11.1.2.Chemotherapeutics 
11.1.3.Targeted Therapeutics 
11.1.4.Others
11.2.  Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Lung NET
11.2.2.Others NET
11.2.3.Gastrointestinal NET
11.2.4.Pancreatic NET
11.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital Pharmacies
11.3.2.Retail Pharmacies
11.3.3.Others
11.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Neuroendocrine Tumors Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Somatostatin Analogues 
12.1.2.Chemotherapeutics 
12.1.3.Targeted Therapeutics 
12.1.4.Others
12.2.  Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Lung NET
12.2.2.Others NET
12.2.3.Gastrointestinal NET
12.2.4.Pancreatic NET
12.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital Pharmacies
12.3.2.Retail Pharmacies
12.3.3.Others
12.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Neuroendocrine Tumors Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Somatostatin Analogues 
13.1.2.Chemotherapeutics 
13.1.3.Targeted Therapeutics 
13.1.4.Others
13.2.  Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Lung NET
13.2.2.Others NET
13.2.3.Gastrointestinal NET
13.2.4.Pancreatic NET
13.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospital Pharmacies
13.3.2.Retail Pharmacies
13.3.3.Others
13.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Pfizer Inc., (U.S)
14.2.2.Eli Lilly & Company (U.S.)
14.2.3.Novartis AG (Switzerland)
14.2.4.F. Hoffmann-La Roche Ltd.(Switzerland)
14.2.5.Ipsen (France)
14.2.6.Amgen, Inc. (U.S.)
14.2.7.Teva Pharmaceuticals, Ltd. (Israel)
14.2.8.Bristol-Myers Squibb (U.S.)
15. Research Methodology 
16. Appendix and Abbreviations 
  • Pfizer Inc., (U.S)
  • Eli Lilly & Company (U.S.)
  • Novartis AG (Switzerland)
  • F. Hoffmann-La Roche Ltd.(Switzerland)
  • Ipsen (France)
  • Amgen, Inc. (U.S.)
  • Teva Pharmaceuticals, Ltd. (Israel)
  • Bristol-Myers Squibb (U.S.)

Adjacent Markets